Osteosarcoma – Global Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteosarcoma
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Osteosarcoma – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Osteosarcoma (Oncology), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Osteosarcoma and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies/Universities/Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages are 1, 31, 7, 1, 26 and 6 respectively.
Similarly, the Universities portfolio in Phase II, Phase I, Preclinical
and Discovery stages comprises 2, 4, 3 and 3 molecules, respectively.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Osteosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Osteosarcoma
  (Oncology) by companies and universities/research institutes based on
  information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Osteosarcoma
  (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Osteosarcoma (Oncology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Osteosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Osteosarcoma (Oncology) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Osteosarcoma – Overview
3. Therapeutics Development
4. Therapeutics Assessment
5. Companies Involved in Therapeutics Development
6. Drug Profiles
7. Dormant Projects
8. Discontinued Products
9. Product Development Milestones

Companies Mentioned

• Aadi Bioscience Inc
• Advanced BioDesign
• Advenchen Laboratories LLC
• Amgen Inc
• AntiCancer Inc
• APEIRON Biologics AG
• Arrowhead Pharmaceuticals Inc
• Autolus Therapeutics Plc
• Bayer AG
• Bellicum Pharmaceuticals Inc
• BioMed Valley Discoveries Inc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Co
• Celgene Corp
• Cellectar Biosciences Inc
• Cellestia Biotech AG
• Cellmid Ltd
• CorMedix Inc
• Eisai Co Ltd
• Eleison Pharmaceuticals LLC
• Endocyte Inc
• Exelixis Inc
• GlycoMimetics Inc
• Intezyne Inc
• Iovance Biotherapeutics Inc
• Ipsen SA
• Isofol Medical AB
• Jiangsu Hengrui Medicine Co Ltd
• Kitov Pharma Ltd
• MacroGenics Inc
• Mateon Therapeutics Inc
• MD Biosciences GmbH
• MedImmune LLC
• Merck & Co Inc
• Merck KGaA
• Nektar Therapeutics
• Nkarta Inc
• Novartis AG
• Oncolix Inc
• Ono Pharmaceutical Co Ltd
• Pfizer Inc
• Provectus Biopharmaceuticals Inc
• Scancell Holdings Plc
• Sorrento Therapeutics Inc
• Teijin Pharma Ltd
• Tyme Technologies Inc
• United Therapeutics Corp
• Vaccinex Inc
• VCN Biosciences SL
• Y-mAbs Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jx1yt8

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs